Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks
In testimony prepared for a Congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.
Read more on NPR
September 21, 2016 at 11:30PM
Health Care
NPR News: Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks
Related Posts:
NPR News: Morehouse College President Talks About HBCU Meeting With Trump- NPR News: Forbidding Forecast For Lyme Disease In The Northeast
- NPR News: Forbidding Forecast For Lyme Disease In The Northeast
- NPR News: Working Class Students Answer: Is College Worth It?
- NPR News: If You Get Bit By a Lyme-Infested Tick, Here Are 5 Tips
0 nhận xét:
Đăng nhận xét